Mission Therapeutics announces new non-executive chairman
pharmafile | December 5, 2016 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Mission Therapeutics, appointment
Drug discovery and development firm Mission Therapeutics has announced that it has appointed Dr Colin Goddard (pictured) as non-executive chairman effective 1 January, 2017, while founder chairman Michael Moore transitions to the role of deputy chairman.
Goddard initially joined the board as non-executive director in July 2015. He previously served at OSI Pharmaceuticals as CEO since 1998, having worked at the company since 1989. OSI was acquired by Astellas Pharma in 2010 for $4 billion.
“On behalf of the Board, it gives me great pleasure to welcome Colin in his new role as the company progresses to the next phase of its evolution,” commented Moore. “I look forward to continuing to work with him and the Board of Directors as, together with an outstanding management team we continue to shape the Company’s strategy. Colin’s timely accession extents the business reach of Mission commensurate with the significant advances in R&D.”
Goddard himself responded: “I would like to thank Michael for his guidance and support since joining the Board and I look forward to working with the Executive team and my Board colleagues as we build on Mission’s achievements to date. I firmly believe that the Company’s innovative DUB platform can yield transformational, first in class new therapies that address a broad range of unmet clinical needs.
Mission Therapeutics’ primary focus lies in the treatment of cancer, neurodegenerative diseases and other ailments through treatment developments which selectively target deubiquitylating enzymes (DUBs).
The company’s CEO Dr Anker Lundemose also gave comment on the appointment: “We would like to thank Michael for his robust support and broad expertise during the formative period of the Company and for his role in nurturing the establishment of a powerful drug discovery platform and emerging product pipeline. Colin has a long track record of leadership and success in the industry including as Executive Chairman and CEO of both public and private US biopharma companies and we look forward to leveraging his experience as we exploit our pipeline and transition into a clinical stage company.”
Related Content
FDA approves Mission Therapeutics’ phase 2 clinical trial for acute kidney injury treatment
Mission Therapeutics has announced that the US Food and Drug Administration (FDA) has approved its …
Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …
Abbott CEO to step down after 21 years
After more than two decades at the head of the company, it has emerged that …